182 related articles for article (PubMed ID: 32145342)
1. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
[TBL] [Abstract][Full Text] [Related]
2. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
[TBL] [Abstract][Full Text] [Related]
3. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
5. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.
Roland CL; Nassif Haddad EF; Keung EZ; Wang WL; Lazar AJ; Lin H; Chelvanambi M; Parra ER; Wani K; Guadagnolo BA; Bishop AJ; Burton EM; Hunt KK; Torres KE; Feig BW; Scally CP; Lewis VO; Bird JE; Ratan R; Araujo D; Zarzour MA; Patel S; Benjamin R; Conley AP; Livingston JA; Ravi V; Tawbi HA; Lin PP; Moon BS; Satcher RL; Mujtaba B; Witt RG; Traweek RS; Cope B; Lazcano R; Wu CC; Zhou X; Mohammad MM; Chu RA; Zhang J; Damania A; Sahasrabhojane P; Tate T; Callahan K; Nguyen S; Ingram D; Morey R; Crosby S; Mathew G; Duncan S; Lima CF; Blay JY; Fridman WH; Shaw K; Wistuba I; Futreal A; Ajami N; Wargo JA; Somaiah N
Nat Cancer; 2024 Apr; 5(4):625-641. PubMed ID: 38351182
[TBL] [Abstract][Full Text] [Related]
6. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
[TBL] [Abstract][Full Text] [Related]
7. Enhanced development of functional human NK cells in NOD-scid-IL2rg
Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA
FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876
[TBL] [Abstract][Full Text] [Related]
8. An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer.
Shang P; Yu L; Cao S; Guo C; Zhang W
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1497-1506. PubMed ID: 36269133
[TBL] [Abstract][Full Text] [Related]
9. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J
MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780
[TBL] [Abstract][Full Text] [Related]
10. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
13. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
Laing ST; Griffey SM; Moreno ME; Stoddart CA
J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
[TBL] [Abstract][Full Text] [Related]
14. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
15. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry Prediction for Clinical Translation of
Natarajan A; Patel CB; Habte F; Gambhir SS
Sci Rep; 2018 Jan; 8(1):633. PubMed ID: 29330552
[TBL] [Abstract][Full Text] [Related]
18. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
19. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
